News Sanofi, J&J abandon trial of E coli vaccine after poor data Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.
News GH Research leaps on psychedelic data in depression After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.
News J&J's Spravato gets another lift with new FDA approval Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
News EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
News J&J files intravesical bladder cancer drug TAR-200 in US Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face